Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of various repeat-dose regimens of KB003 in subjects with active Rheumatoid Arthritis (RA) who have had an inadequate prior treatment outcome from biologic therapy.

Key facts

Study ID

NCT00995449

Run by

Humanigen, Inc.

People needed

9

Starts

2010-01-01

Expected to finish

2012-02-01

Last updated by the study team

2014-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 6 swollen and at least 6 tender joints
• C-reactive Protein (CRP) > Upper Limit Normal (ULN)
• Prior inadequate response from biologic therapy
• Stable regimens of concomitant RA therapies

You may not qualify if…

• Unstable medical conditions

Where it is running

• Study site — Stanford, California, United States
• Study site — Westlake Village, California, United States
• Study site — Miami, Florida, United States
• Study site — Honolulu, Hawaii, United States
• Study site — Frederick, Maryland, United States
• Study site — Wheaton, Maryland, United States
• Study site — St Louis, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Wilmington, North Carolina, United States
• Study site — Tulsa, Oklahoma, United States
• Study site — Oak Creek, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.